{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:22:47Z","timestamp":1794352967024,"version":"4.9.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.05.004","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:16:21Z","timestamp":1779754581000},"page":"13-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-8446","authenticated-orcid":false,"given":"Shugo","family":"Yajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Imasato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genichiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.05.004_bib0001","unstructured":"IARC. Cancer Today. Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today. Accessed March 19, 2025."},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.05.004_bib0003","article-title":"The financial burden of localized and metastatic bladder cancer","author":"Scilipoti","year":"2024","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2026.05.004_bib0004","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.urology.2017.07.016","article-title":"The burden of cystoscopic bladder cancer surveillance: anxiety, discomfort, and patient preferences for decision making","volume":"108","author":"Koo","year":"2017","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.004_bib0005","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.004_bib0006","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.004_bib0007","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: monitoring cancer-genetics in the blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.004_bib0008","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11912-024-01555-0","article-title":"From detection to cure - emerging roles for urinary tumor DNA (utDNA) in bladder cancer","volume":"26","author":"Linscott","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"10.1016\/j.urolonc.2026.05.004_bib0009","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/diagnostics12112696","article-title":"Detection of urinary molecular marker test in urothelial cell carcinoma: a review of methods and accuracy","volume":"12","author":"Bulai","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.urolonc.2026.05.004_bib0010","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.urolonc.2026.05.004_bib0011","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jclinepi.2003.12.019","article-title":"Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full bayesian analysis","volume":"57","author":"Macaskill","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2026.05.004_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","article-title":"Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies","volume":"15","author":"R\u00f6ver","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.004_bib0013","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","article-title":"Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer","volume":"29","author":"Christensen","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0014","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-024-01974-4","article-title":"Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial","volume":"23","author":"Wu","year":"2024","journal-title":"Mol Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003732","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: a cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.urolonc.2026.05.004_bib0016","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.3390\/cancers15102868","article-title":"Accurate detection of urothelial bladder cancer using targeted deep sequencing of urine DNA","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.urolonc.2026.05.004_bib0017","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1002\/1878-0261.13639","article-title":"Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer","volume":"18","author":"Vedeld","year":"2024","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0018","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1038\/s41598-017-05623-3","article-title":"Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer","volume":"7","author":"Patel","year":"2017","journal-title":"Sci Rep."},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.004_bib0019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/cas.16025","article-title":"Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma","volume":"115","author":"Tamura","year":"2024","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic alterations in liquid biopsies from patients with bladder cancer","volume":"70","author":"Birkenkamp-Demtr\u00f6der","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.004_bib0021","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jmoldx.2024.01.006","article-title":"The clinical validity of urinary pellet DNA monitoring for the diagnosis of recurrent bladder cancer","volume":"26","author":"Abe","year":"2024","journal-title":"J Mol Diagn"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.004_bib0022","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.urolonc.2012.07.013","article-title":"Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data","volume":"31","author":"Casadio","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.05.004_bib0023","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ebiom.2019.05.004","article-title":"Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer","volume":"44","author":"Avogbe","year":"2019","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.urolonc.2026.05.004_bib0024","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.urolonc.2019.06.010","article-title":"Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer","volume":"37","author":"Borkowska","year":"2019","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.05.004_bib0025","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1111\/cas.14155","article-title":"Genomic profile of urine has high diagnostic sensitivity compared to cytology in non-invasive urothelial bladder cancer","volume":"110","author":"Hirotsu","year":"2019","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2026.05.004_bib0026","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.eururo.2016.06.035","article-title":"A prospective blinded evaluation of urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria","volume":"70","author":"Dahmcke","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.004_bib0027","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/cas.14000","article-title":"Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma","volume":"110","author":"Hayashi","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.urolonc.2026.05.004_bib0028","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clinbiochem.2018.11.009","article-title":"Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer","volume":"64","author":"Stasik","year":"2019","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.004_bib0029","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bju.14808","article-title":"Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification","volume":"124","author":"Ward","year":"2019","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.004_bib0030","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.juro.2012.11.115","article-title":"Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project","volume":"189","author":"Zuiverloon","year":"2013","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2026.05.004_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA445","article-title":"Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non\u2013muscle-invasive bladder cancer: a prospective study","volume":"41","author":"Rose","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2026.05.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4600","article-title":"Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC)","volume":"42","author":"Linscott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.004_bib0033","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JU.0000000000001878","article-title":"Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer","volume":"206","author":"Zhang","year":"2021","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.05.004_bib0034","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/ejhg.2015.281","article-title":"Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA","volume":"24","author":"Togneri","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"4S","key":"10.1016\/j.urolonc.2026.05.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2016.02.2496","article-title":"MP13-15 Molecular urine cytology \u2013 Bladder EpiCheck is a novel molecular diagnostic tool for monitoring of bladder cancer patients","volume":"195","author":"Wasserstrom","year":"2016","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0036","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00345-025-05453-3","article-title":"Predictive value of Bladder EpiCheck\u00ae in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer","volume":"43","author":"S\u00fczan","year":"2025","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.05.004_bib0037","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22246","article-title":"Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer","volume":"128","author":"Trenti","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"10.1016\/j.urolonc.2026.05.004_bib0038","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncy.22152","article-title":"Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer","volume":"127","author":"Trenti","year":"2019","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.004_bib0039","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.004_bib0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/23523735241304348","article-title":"North American study and meta-analysis evaluating performance of Bladder EpiCheck\u00ae, a FDA cleared test, in non-muscle invasive bladder cancer recurrence","volume":"10","author":"Fleshner","year":"2025","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2026.05.004_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2022.03.009","article-title":"The role of Bladder Epicheck test in follow-up of patients with non-muscle invasive bladder cancer","volume":"20","author":"Ragonese","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.004_bib0042","doi-asserted-by":"crossref","first-page":"105.e11","DOI":"10.1016\/j.urolonc.2021.11.001","article-title":"Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: a single centre, prospective, blinded clinical trial","volume":"40","author":"Cochetti","year":"2022","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.05.004_bib0043","doi-asserted-by":"crossref","first-page":"195","DOI":"10.23736\/S2724-6051.23.05488-5","article-title":"Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck\u00ae as a diagnostic tool in upper urinary tract tumor","volume":"76","author":"Palermo","year":"2024","journal-title":"Minerva Urol Nephrol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.05.004_bib0044","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JU.0000000000002748","article-title":"DNA methylation urine biomarkers test in the diagnosis of upper tract urothelial carcinoma: results from a single-center prospective clinical trial","volume":"208","author":"Territo","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40364-024-00682-x","article-title":"Comparison and combination of mutation and methylation-based urine tests for bladder cancer detection","volume":"12","author":"Gordon","year":"2024","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0046","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.euo.2022.03.005","article-title":"BladderPath Trial Management Group. Highly sensitive and specific detection of bladder cancer via targeted ultra-deep sequencing of urinary DNA","volume":"6","author":"Ward","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2026.05.004_bib0047","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.urolonc.2026.05.004_bib0048","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.eururo.2024.10.014","article-title":"Sensitive detection of urothelial cancer via high-volume urine DNA analysis","volume":"87","author":"Nikkola","year":"2025","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:29:27Z","timestamp":1783376967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1078143926005235"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic performance of urinary tumor DNA in urothelial carcinoma: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}